EpiEndo begins trial of chronic obstructive pulmonary disease treatment

EpiEndo Pharmaceuticals has obtained regulatory and ethics approval to begin a Lipopolysaccharide (LPS) challenge clinical trial of its lead molecule, EP395, to treat chronic obstructive pulmonary disease (COPD).